Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Back to the forum  2018-07-22 23:49 CEST (UTC+2h)

Shenanigans [BE/BA News]

posted by ElMaestro - Denmark, 2018-04-15 14:50  - Posting: # 18684
Views: 438

Hi all,

story from New York Times.

I have seen some cases of the same phenomenon in Europe, when wholesalers have been very forthcoming with supplies of trial material until they are told it is for use as a comparator in a BE trial. Then suddenly there is 'a problem with the supply chain' or some such vague excuse for quickly terminating the call.

if (3) 4

Best regards,
ElMaestro

"(...) targeted cancer therapies will benefit fewer than 2 percent of the cancer patients they’re aimed at. That reality is often lost on consumers, who are being fed a steady diet of winning anecdotes about miracle cures." New York Times (ed.), June 9, 2018.

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,547 posts in 3,941 threads, 1,190 registered users;
online 19 (0 registered, 19 guests [including 17 identified bots]).

Ignorance more frequently begets confidence
than does knowledge.    Charles Darwin

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed